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A B S T R A C T
The production of antibodies is accompanied by a slight excess of synthesis of κ and λ immunoglobulin light
chains; small amounts of them are released in the peripheral blood and can also be found in various body fluids,
such as synovial fluid, cerebrospinal fluid, urine and saliva. They are rapidly filtered by the glomerulus
and> 99% are reabsorbed from the cells of the proximal convoluted tubule, making them present in the urine in
only trace amounts. The production of an excess of protein without a reason or a specific function in a biological
system is rare. Free light chains, considered for years a waste product of Ig synthesis, are currently known to be
very active molecules, able to bind antigens as well as whole immunoglobulin and helping to develop specific
antibody affinity. The ability of free light chains to activate mast cells and then become an active part of the
pathogenic mechanisms of chronic inflammatory diseases has increased interest in their clinical use, both as an
attractive therapeutic target or as a biochemical marker of disease evolution or remission.
This is an overview of relevant scientific interest that immunoglobulin light chains κ and λ have attracted
over the years, a report on the progress in knowledge about their structure and function, with a special focus on
their biological meaning and potential clinical utility in different diseases.
1. Introduction
Immunoglobulin (Ig) free light chains κ and λ (FLCs) have always
been the subject of great scientific interest, and the progress in
knowledge about their structure and function have characterized the
history of medicine, beginning with Henry Bence Jones (Bence, 1847),
Paul Ehrlich (Ehrlich, 1900) and Arne W. Tiselius (Tiselius and Kabat,
1939), who won the Nobel prize in 1948. These early frontrunners were
followed by Frank W. Putnam and Ingemar Berggård, who sought the
physico-chemical and structural characteristics of FLCs (Putnam and
Hardy, 1955; Berggård and Peterson, 1969). The FLC molecular defi-
nition is attributable to Gerald M. Edelman (Edelman and Gaily, 1962)
and Rodney R. Porter (Porter, 1973). The numerous experimental stu-
dies of Alan Solomon (Solomon, 1976) and Karsten Sølling (Sølling and
Sølling, 1979) have also played a fundamental role in describing these
proteins.
The development of FLCs assays began in the early 1960s and for
over 30 years there have been rudimentary semi-quantitative methods,
such as simple and radial immunodiffusion (Mancini method) (Mancini
et al., 1965), quantitative methods easily practicable but with poor
reproducibility, such as the first radio-immunoassays (SøIling, 1975)
which were subsequently made more reliable (Robinson et al., 1982),
up to the development of non-radioisotope immunological methods,
such as immunoassays (Brouwer et al., 1985), turbidimetric (Tillyer
et al., 1991). These assays were not considered able to truly determine
FLCs, but probably were measuring total (free and bound) light chains.
In 2001 an assay for determining plasma FLCs was found, characterized
by the use of specific polyclonal antibodies able to selectively bind to
the free chains (Bradwell et al., 2001). This technique was subsequently
progressively improved (Briand et al., 2010).
Afterwards, a nephelometric assay using a mixture of monoclonal
antibodies (Levinson, 1992; Te Velthuis et al., 2011; Pretorius et al.,
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2012), multiplex platforms (Campbell et al., 2016) and finally the most
recent mass spectrometry (VanDuijn et al., 2015) were applied to FLCs
determination. For the first time the International Myeloma Working
Group (IMWG) incorporated the FLCs measurement in the 2009
guidelines (Dispenzieri et al., 2009). Since then, numerous guidelines
have demonstrated the importance of the FLC assay in the evaluation
and monitoring of therapy outcomes, assessment of the prognosis of
diseases caused by immunoglobulin deposition and of immune-pro-
liferative disorders (Charafeddine et al., 2012; Graziani and Merlini,
2014). Recently, the IMWG guidelines have highlighted the importance
of using an appropriate test for the correct interpretation of the κ/λ
ratio in defining different degrees of smoldering multiple myeloma
(SMM) (Rajkumar et al., 2014).
The different forms of molecular aggregation of FLCs, such as
monomers, dimers, tetramers, and other polymeric forms (Sølling,
1976), their monoclonal polymorphism, arising from the proliferation
of different plasma cell clones, make it difficult to achieve an adequate
accurancy for these measurements (Jacobs et al., 2016).
The correlation between two different assays is better for κ than λ
FLC. The two assays are not entirely equivalent. Care should be taken
by interpreting physicians and laboratories when considering switching
assays (Cigliana et al., 2017).
Until a few years ago, the interest in FLC measurement was confined
to the measurement of monoclonal FLCs (mFLCs) for the management
of patients with a monoclonal component. The present contribution is
dedicated to polyclonal FLCs (pFLCs) and their measurement as a new
biomarker for monitoring diseases and treatment of pathologies dif-
ferent from plasma cell dyscrasia.
2. Expression of pFLCs in the immune response
Early studies on antibody production, typical of the acquired im-
mune response, showed a slight excess by synthesis of immunoglobulin
light chains, giving rise to a release of about 500 mg/day of pFLCs in
the peripheral blood (Boivin et al., 2004). pFLCs can also be found in
various body fluids, such as synovial fluid, cerebrospinal fluid (CSF),
urine and saliva.
pFLCs are rapidly filtered by the glomerulus and> 99% are re-
absorbed from the cells of the proximal convoluted tubule, making
them present in the urine in only trace amounts. The production of an
excess of protein without a reason or a specific function in a biological
system is rare; FLCs should therefore be considered bioactive molecules
rather than a secondary product of the synthesis of immunoglobulins
(Ig) without any functional relevance. Numerous studies have eluci-
dated the biological role of pFLCs, in the following main functions:
enzymatic (including anti-angiogenic activities), κ light chain is the first
molecule associated with the anti-angiogenic activity of Neovastat, an
anti-angiogenic extract from shark cartilage (Boivin et al., 2004); pro-
teolytic, pFLCs displayed hydrolytic activity against inactivated va-
soactive intestinal peptide (Sun et al., 1994; Paul et al., 1995); pro-
thrombinase activities, conversion of fibrinogen to fibrin was
accelerated by the prothrombin fragments generated by the light chain.
These finding suggested a novel mechanism whereby antibodies can
induce a pro-coagulant state (Thiagarajan et al., 2000); complement
activation, in vitro the λ light chain dimer efficiently activates the al-
ternative pathway of complement and represents the first described
pathogenic mini-autoantibody in human disease (Jokiranta et al.,
1999); specific binding to substrates and enzymes, including protein
and non-protein antigens, pFLCs can sensitize mast cells, such that a
second encounter with the antigen results in mast-cell activation
(Redegeld and Nijkamp, 2003; Van den Beucken et al., 2001); chemo-
tactic factors, X-ray crystallographic techniques showed the binding
ways of N-formylated chemotactic peptides to the light chain (Bence-
Jones) dimer (Edmundson and Ely, 1985); Enkephalins and beta-caso-
morphins (opioid peptides) were found to bind in a variety of con-
formations to a human light chain dimer from a patient with amyloi-
dosis (Edmundson et al., 1987); binding cells, including mast cells,
pFLCs have a crucial role in development of contact sensitivity. Al-
though IgE and IgG are central to the induction of immediate hy-
persensitivity reactions, these results showed that FLC have a similar
activity (Redegeld et al., 2002); in renal tubular cells pFLCs endocytosis
leads to production of inflammatory cytokines. This may be an im-
portant mechanism of chronic tubule-interstitial inflammation process
(Sengul et al., 2002). Experimental studies have delineated important
aspects regarding the interactions between glomerulopathic pFLCs and
mesangial cells, indicating that these interactions are receptor mediated
(Teng et al., 2004); in B lymphocytes were defined a new property of
pFLCs that inhibits the autonomous signaling ability of the B-cell
Fig. 1. Biological roles of pFLCs.
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receptor (Foy and Matsuuchi, 2001; Meixlsperger et al., 2007).
The properties of pFLCs are schematically represented in Fig. 1.
The presence of pFLCs in the circulation is directly related to plasma
cell activity: for example, the proliferation of a secreting plasma cell
clone causes an increase in mFLCs in serum and other biological fluids
(i.e. urine). In this case, the FLCs are identical and monoclonal, only
electrophoresis is able to highlight the characteristic monoclonal mor-
phology. However, in many diseases, including those with a decreased
kidney filtration rate and chronic inflammatory diseases characterized
by B cell activation, pFLCs have been reported to increase, representing
a finding of clinical interest (Hutchison and Landgren, 2011). It would
be interesting to evaluate the relationship between the pFLCs and the C-
reactive protein in order to assess the possible relationships between
such markers in different chronic inflammatory diseases (Burmeister
et al., 2014). The main difference in polyclonal and mFLCs increases is
the absence of significant alterations in the κ/λ ratio. Some diseases are
frequently associated with increased pFLCs synthesis in serum, CSF,
urine and synovial fluid. FLCs accumulate in the circulation in kidney
diseases, and especially in chronic renal damage, due to reduced glo-
merular filtration rate. pFLC expression was detected in tumor-asso-
ciated tissues from human breast, pancreas, lung, colon, skin and
kidney, while pFLC staining was virtually absent in the corresponding
healthy tissue. pFLCs are biomarkers of poor prognosis in basal-like
breast cancer and are potential targets in tumor-associated inflamma-
tion (Groot Kormelink et al., 2014). pFLCs were co-localized with mast
cell infiltrates in tumor tissue leading to the hypothesis that pFLCs can
activate mast cells occurring in peri-tumoral inflammation (Groot
Kormelink et al., 2014). The clinical significance of pFLCs isotype was
studied in a large cohort of patients with breast cancer in a long-term
follow-up. Kormelink GT et al. showed that pFLCs expression was as-
sociated with an aggressive tumor trait, particularly those with a triple-
negative (estrogen receptor, progesterone receptor and HER2 negative)
basal-like phenotype (Groot Kormelink et al., 2014). The authors sug-
gested that pFLCs activated mast cells are associated with increased
tumor growth in a preclinical tumor model (Groot Kormelink et al.,
2014). Increased pFLCs expression in the stroma of breast cancer tissue
showed an association with reduced survival. This seems to be evident
also in other tumors. Blocking pFLCs with the antagonist F991 could be
a novel strategy for therapeutically modifying mast cell-mediated
cancer growth (Groot Kormelink et al., 2014).
3. pFLCs and autoimmune diseases
Autoimmune diseases are characterized by a chronic inflammatory
condition. Autoimmunity is an immune system defect of either B or T
lymphocytes that are involved in adaptive immune activation.
Autoimmune diseases are classified as systemic autoimmune diseases
and tissue-specific autoimmune diseases. In this scenario, it is con-
ceivable that the ability of pFLCs to activate mast cells and macro-
phages play a relevant, yet not fully clarified role.
The first observations of pFLCs alteration in Rheumatoid Arthritis
(RA) and Systemic Lupus Erythematosus (SLE) date back to the 1960s;
two studies demonstrated that the concentration of pFLCs in serum and
urine, was significantly higher compared to healthy controls. This is the
first observation correlating the concentration of circulating pFLCs with
disease evolution (Epstein and Tan, 1966; Cooper and Bluestone, 1968).
Other subsequent studies showed the possibility of pFLCs as biomarkers
(Sølling et al., 1981; Jolly et al., 2014; Ye et al., 2013).
A similar study conducted by measuring pFLCs with the Freelite
(Binding Site, Birmingham UK) method developed in 2001, confirmed
that the concentration of pFLCs is significantly higher in patients with
autoimmune diseases than in the normal population, in the absence of a
significant alteration of the κ/λ ratio (Gottenberg et al., 2007). Anti-
Ro/SSA (Anti-Sjögren's-syndrome-related antigen A) antibodies are
among the most frequently detected autoantibodies against nuclear
antigens and have been associated with SLE and primary and secondary
Sjögren's syndrome (SS). Although the presence of these autoantibodies
is one of the criteria for the diagnosis and classification of SS, some-
times, they are also seen in other systemic autoimmune diseases. These
antibodies have been used as a useful diagnostic marker for SLE and SS
for decades, even if their pathological significance still remains to be
clarified. Interestingly, in patients with SS, both primary and secondary
to RA, the presence of SS-B/La (anti-Sjögren's syndrome type B) anti-
extractable nuclear antigens is associated with an increased con-
centration of serum pFLCs, while this does not occur in patients with
SS-A/Ro anti-extractable nuclear antigens. The presence of these au-
toantigens is a biomarker of the disease, but is not correlated with its
clinical course in which increased risk of lymphoma could result from
persistent B cell activation and disease activity (Ye et al., 2013). In-
creased concentration of serum pFLCs and β2microglobulin are markers
of disease activity and severity and can be useful for therapeutic
monitoring or to assess recurrences after remission (Gottenberg et al.,
2013).
Few studies have quantified pFLCs in urine, a non invasive sampling
method in patients with different rheumatic diseases. SLE patients have
been shown to have an increase of urinary pFLCs in correlation with
phases of disease activity and a decrease in quiescent phases (Hopper
et al., 2000). Sudden and dramatic increases in urinary pFLCs precede
the development of severe clinical manifestations by 4–8 weeks, re-
flecting activation of B cells (Hopper et al., 1989). However, the results
of these studies can be partially affected by the presence of proteinuria,
typical in patients with SLE, and by the poor reliability of the analytical
methods for the determination of pFLCs in urine. However, more re-
cently, FLCs were measured in plasma of 75 patients with SLE and 41
with RA and the results confirm previous observations obtained in urine
samples (Aggarwal et al., 2011) showing that the magnitude of the FLC
increase in patients with SLE is clearly correlated with the disease ac-
tivity. This study also showed that when pFLCs increase, there was no
alteration of the κ/λ ratio, confirming the polyclonal nature of FLCs.
These data were confirmed in a recent study where pFLCs in urine were
elevated in patients with rheumatic disease, with normal κ/λ ratio. The
correlation between pFLCs and inflammatory markers in patients with
RA demonstrates their potential in predicting disease activity
(Bramlage et al., 2016). Further studies are required to determine
whether FLC assessment could represent a relevant biomarker for re-
sponse to treatment (especially B cell depletion) and for the risk of
lymphoma in autoimmune diseases (Gottenberg et al., 2007). In con-
clusion increased concentration of pFLCs in SLE and RA subjects could
be used as biological markers of disease activity, confirming the interest
of pFLCs concentrations in rheumatic disease (Bramlage et al., 2016;
Draborg et al., 2016).
4. pFLCs and Rituximab
The monoclonal anti-CD20 antibody, Rituximab (RTX), is one of the
most commonly used drugs in the treatment of RA and SLE, especially
in subjects refractory to conventional therapy. RTX acts selectively on
CD20-positive B lymphocytes (mature and pre-B cells), leaving the
plasma cells almost intact. Monitoring the RTX therapy in patients with
SLE and RA is complicated by the lack of effective biochemical markers
and the available ones have a low degree of correlation with the con-
comitant clinical picture. For example, rheumatoid factor and anti-ci-
trulline antibodies usually decrease after RTX treatment, but this does
not always indicate an improvement in the patient's clinical condition,
making the decision of whether or not to suspend therapy difficult
(Mazilu et al., 2014). This scenario explains the lack of consensus re-
garding the best method for assessing the patient's response to RTX and
timing of further treatment (Mazilu et al., 2014). Since the depletion of
B cells from peripheral blood reduces the concentrations of serum
pFLCs, such information suggests a more effective marker for mon-
itoring patients receiving RTX (Basile et al., 2015).
Recent studies have evaluated the use of pFLCs as a marker of the
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therapeutic efficacy of RTX in patients with SLE and RA and the results
seem promising (Chice et al., 2011; Kormelink et al., 2010). Chice's
study showed a significant association between the levels of serum κ-
FLC and the consumption of the C3 complement fraction, that is char-
acteristic of active SLE (Chice et al., 2011). This correlation, never
confirmed previously, was described in a preliminary work correlating
pFLCs with disease activity (Redegeld et al., 2002). This study de-
monstrated for the first time that the correlation between serum FLC
and complement consumption is preserved even after B cell depletion.
The fast turnover of FLCs, particularly of κ ones (< 6 h compared to
20–25 days for total IgG) justified the interest in them as ideal markers
of response to RTX. One important result was the presence of a sig-
nificant correlation between serum pFLCs and IgG, but not between
pFLCs and anti-double strand DNA (dsDNA) antibodies, probably be-
cause IgG is a marker of polyclonal activation of B cells, while anti-
dsDNA antibodies indicate specific B cell responses. The close mon-
itoring of peripheral repopulation of B lymphocytes and of the levels of
anti-dsDNA antibodies was proven to be less useful in the evaluation of
SLE relapses. FLC plasma levels monitoring seems to represent a pro-
mising tool for a more accurate evaluation of both the disease activity
and response to RTX treatment (Chice et al., 2011).
In Kormelink's study (Kormelink et al., 2010) pFLCs were found in
high concentrations in the synovial fluid and tissue of affected joints of
RA patients treated with RTX and positively correlated with plasma
concentrations; furthermore, there was a significant correlation be-
tween pFLCs in synovial fluid and acute phase biochemical markers,
such as erythrocyte sedimentation rate (ESR) and C-reactive protein. In
RA responder patients, B-cell depletion by RTX, 3 and 6 months after
initiation of therapy, induced a significant decrease in FLC serum
concentrations. However, only in “full responder” patients did FLCs fall
within normal ranges, but not always in partial responders, due to the
maintenance of local production in synovial tissues.
To confirm the specificity of pFLCs in RA, one study demonstrated
that they were present in negligible quantities in the synovial fluid and
serum of control patients with osteoarthritis (Burmeister et al., 2014).
pFLC were abundantly present in inflamed joints and their con-
centrations were correlated with disease activity, suggesting that pFLC
were a relevant biomarker for treatment response to rituximab in pa-
tient with RA; this seems to confirm the hypothesis that pFLCs reflect
the efficacy of RTX and not the severity of the disease (Kormelink et al.,
2010).
Interestingly, in contrast to the effect of RTX treatment on serum
FLC concentrations, no significant changes were found in serum FLC
concentrations 6 and 12 weeks after anti-TNF treatment. This suggests
that the changes seen in FLC concentrations after RTX treatment may be
part of the therapeutic action of RTX and are not a general feature of
clinical response to disease treatment (Kormelink et al., 2010).
Actually, no commercially available assay for FLC determination in
synovial fluid has been released yet.
In a retrospective study, pFLCs and their ratio were evaluated in
patients with hepatitis C virus (HCV) related mixed cryoglobulinemia
treated with RTX. This study showed that pFLCs and their ratio had
predictive value, being important in assessing the patient's response to
therapy (Bramlage et al., 2016). Based on all these results, it appears
that the determination of pFLCs in association with conventional mar-
kers (i.e., rheumatoid factor and anti-citrulline antibodies) could be of
clinical utility.
5. pFLCs and immediate hypersensitivity
The role of pFLCs in the development of non-IgE mediated hy-
persensitivity reactions has been clarified in the last decade in experi-
mental work on animals and in in vitro studies (Redegeld et al., 2002).
When an antigen binds to mast cells, the pFLCs bind themselves to the
mast cell-antigen complex, prompting the sensitization of an immune-
competent cell that is activated to release inflammatory mediators (Van
den Beucken et al., 2001; Van der Heijden et al., 2006). Ultrastructural
analysis of the activated mast cells by pFLCs reveals the presence of
large-size granules and the formation of degranulation channels for the
fusion of granules themselves (anaphylactic degranulation) (Thio et al.,
2008). The action of pFLCs is inhibited by a specific antagonist, the
peptide F991 (a peptide fragment of the Tamm-Horsfall protein that
acts as a binding site for the FLCs) that selectively blocks the FLC-
mediated hypersensitivity reaction, while not exercising this type of
action in IgE- and IgG1-mediated reactions (van Houwelingen et al.,
2007).
In an animal model study, the administration of F991 in non-atopic
asthma completely eliminates airway obstruction and lung inflamma-
tion (Kraneveld et al., 2002). In addition, F991 inhibits the infiltration
of neutrophils in bronchoalveolar fluid and the development of tracheal
hyper-reactivity. There are relatively few clinical studies evaluating the
utility of FLC determination in the evaluation of patients with allergic
diseases. However, there is evidence that circulating pFLCs significantly
increase in subjects with allergic asthma (Kraneveld et al., 2005), al-
lergic and non-allergic rhinitis (Powe et al., 2010), atopic dermatitis
(Kayserova et al., 2010), idiopathic pulmonary fibrosis (Groot
Kormelink et al., 2011), chronic obstructive pneumonia (Braber et al.,
2012) and allergies to milk proteins (Schouten et al., 2010).
pFLCs play an important role in chronic inflammations of the air-
ways: it has been shown that the number of FLC secreting cells is
greater in the nasal mucosa of subjects with chronic rhinitis than in
controls (Thio et al., 2008). The role of pFLCs in the pathophysiology of
allergic asthma is to mediate the antigen-specific response of mast cells;
in fact, in a murine model, in vitro and in vivo studies showed that
pFLCs induce the activation of mast cells in response to antigenic ex-
posure, and are co-responsible for the clinical symptoms (i.e., exudation
of mucous and airway hyper-reactivity). Confirmation of the key role of
pFLCs in these diseases derives from the observation that, in an animal
model, the intravenous injection of F991 inhibits the mast cells re-
sponse after sensitization with the antigen (van Houwelingen et al.,
2007).
Confirmation of the FLC location on mast cells of the nasal mucosa
in allergic and non-allergic chronic rhinitis confirms the hypothesis that
pFLCs can promote the extension of the inflammatory phenomenon. In
addition, a close association between pFLCs levels and granulocyte
mediators (i.e., mast cell tryptase and eosinophil cationic protein) was
found, further confirming the involvement of pFLCs in the allergic in-
flammatory cascade. In allergic and non-allergic rhinitis, the increase in
pFLCs similarly occurs for κ and λ chains and stems from the increased
activity of B cells. Analogously with the increase in specific IgE
synthesis characterizing allergic syndromes, this leads to the polyclonal
synthesis of antigen-specific FLCs. According to the recommendations
of the European Academy of Allergy and Clinical Immunology task
force, idiopathic rhinitis and non-allergic rhinitis with eosinophilia
syndrome, which are FLC-mediated, require a re-classification (Powe
et al., 2010). However, it is necessary to identify the antigens that in-
duce an FLC-mediated mucosal response and to conduct further studies
to better understand the pathophysiology of non-allergic rhinitis
(Johansson et al., 2004).
pFLCs are involved in the early stages of two chronic interstitial
lung diseases: idiopathic pulmonary fibrosis (IPF) and chronic hy-
persensitivity pneumonitis (HP). These are two serious diseases of un-
certain etiology and the pathogenetic mechanisms have not yet been
completely clarified. pFLCs were measured in serum and BAL of 21
patients with IPF, 22 with HP and 15 healthy subjects (controls),
showing significant increases both in serum and in BAL of patients with
IPF and HP (Groot Kormelink et al., 2011). The IgG were also increased
in patients with HP, while no significant difference was observed for
total IgE concentrations in the three groups. However, the mechanism
of activation of mast cells in both pathologies is not yet clear. Another
striking result has been provided by immunohistochemistry that
showed the presence of immunocompetent FLC-secreting cells in the
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lung parenchyma of patients with IPF and HP, but not in the control
group. This suggests an active role of pFLCs in the development of these
two diseases, probably through a common cascade of activation of the
immunological mediators, although the pathogenesis of both diseases is
different. Inhibition of pFLCs could prevent the activation of mast cells
and inhibit the development of allergy, increasing the potential ther-
apeutic interest of these proteins.
6. pFLCs in viral infections
The clinical interest in the determination of pFLCs in human im-
munodeficiency virus (HIV) or hepatitis C virus (HCV) patients comes
from the observations about the possible role of their increase as an
early biomarker of tumor onset, especially lymphomas (Bibas et al.,
2012). In chronic HIV infection, in addition to a progressive loss of CD4
lymphocytes, a series of functional abnormalities of B cells occurs.
These are characterized by low levels of antibody against specific pa-
thogens and poor response to vaccines. Paradoxically, the circulating
levels of immunoglobulins are high, reflecting a non-specific polyclonal
activation of B cells. The result of this B cell disorder is a progressive
immunodeficiency which, in turn, constitutes a risk factor for the onset
of some tumors, such as non-Hodgkin's lymphoma (NHL) (Engels et al.,
2010). In a recent study including> 190 patients with HIV infection, it
was shown that the increase of pFLCs plasma concentration is highly
predictive of NHL risk. Moreover, the risk increases in proportion to the
concentration of pFLCs (Landgren et al., 2010). This result is especially
interesting if we consider that no association between risk of NHL and
IgG, IgA and IgM concentrations was found.
The HCV tropism for lymphatic cells (particularly B cells) has been
correlated with the development of various autoimmune and/or lym-
phoproliferative disorders (Zignego et al., 2007; Paroli et al., 2012) of
which mixed cryoglobulinemia (MC) is the prototype (Sansonno et al.,
2012). HCV patients with MC show a 35-times higher risk of developing
lymphoma than the general population (Monti et al., 2005). MC and B-
cell non-Hodgkin's lymphoma (B-NHL) are the main extrahepatic
manifestations of HCV (Gragnani et al., 2015) and serum levels of
pFLCs have recently been used for monitoring them (Oliveira et al.,
2014).
The determination of FLCs and the κ/λ ratio in patients with HCV
infection may be clinically useful, especially for predicting the onset of
MC. High concentrations of type κ FLCs were observed in HCV-positive
patients with MC and type II MC (characterized by a monoclonal
component that typically uses κ light chains) (Terrier et al., 2009). In
patients with HCV infection, the alteration in the κ/λ ratio is positively
correlated with the increasing severity of the HCV-related lymphopro-
liferative disorder, from cryoglobulinemic vasculitis to NHL, and it is an
early indicator of the activation of lymphoproliferative mechanisms
(Terrier et al., 2009). Finally, it has been observed that the κ/λ ratio
may also be useful in the evaluation of therapeutic efficacy (Basile
et al., 2015).
In a murine model, it has been observed that, after inoculation of a
myocardiotropic variant of the encephalomyocarditis virus and the
subsequent development of viral myocarditis, the synthesis of pFLCs
significantly increases, with a consequent increase in their concentra-
tion in the circulation (Matsumori et al., 2010). The administration of
F991 during the initial period of the infection worsens the clinical
picture, suggesting that pFLCs alter the pathogenesis of the disease by
exercising both a direct inhibition of viral replication and an indirect
anti-inflammatory role. This hypothesis is supported by the observation
that the administration of FLCs in mice infected with en-
cephalomyocarditis virus induces the expression of the interleukin 10
(IL-10) gene and interferon α and γ which can counteract the viral
activity. These studies seem to assign a therapeutic role to FLCs.
However, they are preliminary and need to be confirmed.
The association between pFLCs and antibodies against Epstein-Barr
virus (EBV) has been analyzed in a recent study of EBV-positive patients
with SLE (especially κFLC levels with 69%). The obtained results
showed no correlation between the concentrations of anti-EBV anti-
bodies and those of pFLCs, suggesting that the high concentrations of
pFLCs reflected a reactivation of the virus, and the anti-EBV antibodies
the extent of a previous infection (Draborg et al., 2016). The con-
centration of pFLCs correlated with global disease activity scores, re-
flected inflammation (high CRP and complement consumption) and B
cell activity (high dsDNA antibody titers and total IgG and total IgA
concentrations) in the SLE patients. The results obtained by this study
suggested that the easily quantifiable pFLCs concentrations could be a
supplementary serologic biomarker in SLE (Draborg et al., 2016).
7. pFLCs in multiple sclerosis
Multiple sclerosis (MS) is a chronic inflammatory demyelinating
disease characterized by the intrathecal synthesis of oligoclonal im-
munoglobulins bands (OB), typical of autoimmune inflammatory dis-
eases of the central nervous system (CNS) (Freedman et al., 2005).
Its biological significance relies on the on-site humoral response
reflecting altered regulation of B cells segregated in this compartment.
The detection of OB in CSF is the only biochemical analysis widely used
since late sixties of the last century. Also the assessment of any damage
to the blood-brain barrier, through the ratio index measurement of al-
bumin and immunoglobulins in serum and CSF, becomes part of the
laboratory diagnostics of MS. In the 1970s some clinical studies had
already shown that the disease is characterized by increased pFLCs in
the CSF and in urine, particularly the κ FLC (Eickhoff et al., 1978;
Rudick et al., 1989). At that time, using the determination of pFLCs in
the CSF for the diagnosis and evaluation of patients with MS was
considered unreliable (Rudick et al., 1985). Subsequently, several stu-
dies have evaluated pFLCs in the CSF of MS patients (Lamers et al.,
1995; Krakauer et al., 1998), with more recent ones employing new
analytical methods (Fischer et al., 2004; Presslauer et al., 2008)
showing that pFLCs can be a viable alternative. It has been demon-
strated that the absolute concentrations of the κ-FLCs are highly sen-
sitive and specific for the diagnosis of clinically isolated syndromes, as
well as the relapse and primary progression of MS (Hassan-Smith et al.,
2014). One of the advantages of using pFLCs in diagnostics is that the
CSF allows FLCs to have a longer half-life here than in plasma (2–6 h),
comparable to that of other proteins. Consequently, changes in CSF-
FLCs concentration are able to accurately represent even modest in-
creases in pFLCs intrathecal synthesis. This is particularly useful in the
early recognition of the evolution to MS of any clinical isolated syn-
drome such as optic neuritis or brain stem injury. A recent study
showed that in patients who have had a clinical isolated syndrome, the
increase of CSF-κFLCs was closely related to the risk of evolution of
these diseases into MS (Ramsden, 2017).
In this study, the sensitivity and specificity of FLCs were very similar
to those of the analysis of oligoclonal bands in the CSF (respectively
90.0% vs 90.2% and 82.1% vs 85.1%), but with a lower analytical time
and complexity. The normalized multivariate analysis by sex, age and
basal lesions detected by brain MRI showed a “hazard ratio” equal to
6.41% (95% confidence interval: 1.88 to 21.78%). Ultimately, a con-
centration of κ-FLC in CSF > 0.53 mg/L is an independent predictor of
conversion of an isolated inflammatory disease into MS (Presslauer
et al., 2016).
Whereas FLCs are also present in serum, they are able to passively
diffuse into the CSF. FLC CSF/serum quotients are plotted against the
CSF/serum ratio of albumin. Albumin being only synthesized in liver
and diffuses just passively into the CSF, the κFLC Index calculated as
[(κFLCCSF / κFLCserum) / Qalbumin] × 1000 that takes into account the
function of the blood–CSF barrier is tentative to increase the diagnostic
accuracy of κFLC determination and to better assess the presence of
intrathecal immunoglobulin synthesis avoiding false positive (Duranti
et al., 2013).
The introduction of technically simple, rapid, quantitative assays for
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determination of CSF κ and λ FLC concentrations can replace the
technically more difficult, time-consuming, qualitative assay of oligo-
clonal bands still used in many hospitals for the diagnosis of MS. The
possibility of assessing the presence of κ FLC monomers or dimers by
Western blotting and the combined use of three derived indices related
to the molecular shape are able to significantly improve the sensitivity
and specificity of FLCs, but this is currently not applicable in daily
clinical practice (Kaplan et al., 2013).
8. pFLCs and Chronic Kidney Disease
FLCs and the kidney are closely related each other. A clear dis-
tinction between polyclonal and mFLCs may be useful to better un-
derstand the pathogenic role of FLCs in determining renal impairment
and damage. Under normal conditions, the synthesis of light chains is
slightly unbalanced, originating a small excess of combined pFLCs
(cFLCs = κFLC plus λFLC) in serum. These cFLCs are readily filtered
through the glomerulus and then almost completely reabsorbed by
proximal tubular cells after binding to the megalin and cubilin het-
erodimeric receptor. As a result, only a small amount of polyclonal
cFLCs appears in the urine of healthy subjects (Maack et al., 1979). On
the other hand, when the production rate of polyclonal cFLCs is
markedly increased, the excess of filtered FLCs overwhelms the capacity
of the megalin and cubilin receptor to reabsorb these polypetides, and
large amounts of cFLCs can be excreted with the urine. In addition,
kidney diseases characterized either by the reduction in glomerular
filtration rate or by proximal tubular cell impairment lead to the in-
crease in cFLCs serum levels and in cFLCs proteinuria, respectively. The
accumulation of pFLCs within the proximal tubule lumen stresses the
mechanism of pFLCs endocytosis and induces a cascade of events in-
cluding: inflammation; activation of redox pathways; transcription of
profibrotic cytokines; tubular cells apoptosis, and ultimately the in-
itiation of the epithelial-mesenchymal transition (Basnayake et al.,
2011; Liu, 2010). The progression of renal fibrosis induces the reduc-
tion in nephron mass that in turn causes an accumulation of pFLCs
within the lumen of distal tubules with the formation of proteinaceous
casts. These casts are frequently recognized in kidney pathology; they
consist of a number of various proteins, including FLCs. Furthermore,
polyclonal cFLCs can impair the function of polymorphonuclear gran-
ulocytes, namely neutrophils, significantly compromising the immune
response. Whether or not FLCs are casually related with the progression
of the renal disease is still unclear (Liu, 2010). However, in patients
with Chronic Kidney Disease (CKD) a close relationship has been de-
monstrated between FLCs accumulation and their toxicity in terms of
cardiovascular disease (CVD) and mortality (Haynes et al., 2011;
Desjardins et al., 2013; Anandram et al., 2012). High serum levels of
cFLCs were found strongly associated with mortality in a large sec-
ondary care cohort including all non-dialysis CKD stages (Hutchison
et al., 2014). In a population with early CKD it was observed a sig-
nificant relationship between high levels of polyclonal cFLCs and the
subsequent mortality risk (Ritchie et al., 2015). Taking into account the
hypothesis that systemic inflammation is a relevant contributor to
cardiovascular disease (CVD) and mortality in CKD (Assi et al., 2015),
this relationship may support the role of polyclonal cFLCs as sensitive
biomarkers of systemic inflammation, capable to add prognostic in-
formation to conventional acute phase biomarkers, such as high sensi-
tive C-reactive protein. Therefore, serum polyclonal cFLCs may become
a sensitive biomarker of adaptive immunity in patients with CKD,
especially for assessing subclinical infections, that in turn can de-
termine the survival of CKD patients.
Due to the inverse relationship between serum FLCs levels and renal
function, there is the need for separate reference ranges for FLCs in the
presence of renal impairment (Hutchison and Landgren, 2011).
There are two nephelometric methods commercially available for
the detection of serum FLCs: Freelite (Binding Site, UK) and N Latex
(Siemens Healthineers, Germany), which display different results in
FLC concentration in CKD patients compared with non-CKD patients,
higher in the former group. The parallel increase of both polyclonal κ
and λ FLCs in CKD patients results in the small changes in κ/λ ratio, for
this reason there is no need of adopting different reference limits re-
spect to that used for healthy individuals (Tonelli et al., 2005).
9. Conclusions
FLCs, considered for years a waste product of Ig synthesis, are
currently known to be very active molecules. FLCs are able to bind
antigens as well as whole immunoglobulins, helping to develop specific
antibody affinity.
The ability of pFLCs to activate mast cells and become an active part
of the pathogenic mechanisms of chronic inflammatory diseases has
increased the interest in their clinical use, both as an attractive ther-
apeutic target or as a biochemical marker of disease evolution or
Fig. 2. Diseases where the FLCs may be introduced in clinical
practice.
COPD = chronic obstructive pulmonary disease,
IPF = idiopathic pulmonary fibrosis, SLE = Systemic Lupus
Erythematosus, RA = Rheumatoid Arthritis, AIDS = acquired
immune deficiency syndrome.
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remission.
The delineation of a patients population with pFLC-induced asthma
has a potential therapeutic relevance; in fact, FLC antagonist adminis-
tration may prevent or ameliorate the adverse manifestation in patients
with this often invalidating and occasionally fatal bronchopulmonary
disease.
The role of pFLCs in multiple sclerosis is probably the best studied of
relevant pathologies, with an important number of diagnostic accuracy
studies, therefore κFLC determination should become a first line
screening in the diagnostic algorithms of MS.
In patients with autoimmune or viral diseases, plasma concentration
of pFLCs can be considered a biomarker of both disease activity and the
effectiveness of RTX treatment, highlighting the key role of pFLCs in
chronic inflammatory diseases.
In conclusion, still limited, but very interesting data exist about the
clinical utility of pFLC determination in various conditions, strongly
suggesting that this biomarker could represent a helpful tool in the
clinic, although more well-designed studies are needed before the use of
pFLCs can be suggested (Fig. 2). Even if there are no results that show
improved clinical outcomes through their monitoring, certainly the use
of this biomarker with its interesting physiopathological features could
be of additional help in clinical care.
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